###### Strengths and limitations of this study

-   This study explored the association between alkaline phosphatase (ALP) and in-hospital mortality in 6368 acute coronary syndrome patients undergoing percutaneous coronary intervention.

-   This study also confirmed whether ALP could improve the prognostic performance of Global Registry of Acute Coronary Events score.

-   In this study, data on serum parathyroid hormone level, serum vitamin D level and dietary vitamin D intake was not obtained, which might affect ALP levels.

-   In this study, coronary calcification was assessed by angiography, which might underestimate the frequency and degree of coronary calcium.

Introduction {#s1}
============

Patients with acute coronary syndrome (ACS) usually surfer a poor prognosis.[@R1] The timely prognostic evaluation and adequate clinical treatment is important for the improvement of the prognosis in patients with ACS. Coronary artery calcium contributes to atherosclerosis, and is also a predictor of adverse cardiovascular events.[@R5] Inorganic pyrophosphate is an inhibitor of vascular calcification. As a membrane-bound metallo enzyme, alkaline phosphatase (ALP) catalyses inorganic pyrophosphate and may promote vascular calcification.[@R8] Some studies found that elevated serum ALP was associated with the coronary artery calcium score assessed by CT scanning and the severity of coronary artery disease (CAD).[@R9] Other studies confirmed the association between higher ALP and the long-term adverse outcomes in patients with CAD,[@R11] ACS[@R14] and ST-segment elevation myocardial infarction (STEMI).[@R16] However, the role of ALP level in predicting in-hospital mortality in patients with ACS is not clearly defined.

The Global Registry of Acute Coronary Events (GRACE) score can predict in-hospital mortality in ACS and helps us discriminate high-risk patients.[@R1] However, new markers are not included in GRACE score, such as ALP.

In this study, we aimed to assess whether ALP was a useful clinical parameter to predict in-hospital mortality in patients with ACS undergoing percutaneous coronary intervention (PCI). We also confirmed whether ALP could improve the prognostic performance of GRACE score.

Methods {#s2}
=======

Study design and setting {#s2-1}
------------------------

This prospective cohort study took place at a large-scale hospital in Northeast China (Shengjing Hospital of China Medical University, Shenyang, China). The consecutive patients with ACS undergoing PCI at from 1 January 2010 to 31 December 2017 were eligible for this study. ACS was defined according to the current guidelines.[@R1] PCI was performed in accordance with the current guidelines.[@R1] Clinical data and procedural data of all cases were gained by the investigators using a uniform questionnaire. GRACE score were determined as defined previously.[@R1] In all cases, venous blood samples were drawn on admission in standard tubes. Tissue-non-specific ALP and serum creatinine were measured by a completely automated biochemistry-immunity analyser (Ci 16200, Abbott, USA) in the core laboratory of Shengjing Hospital. The reference interval of ALP in our laboratory was 40--150 U/L. In-hospital death was determined as defined previously.[@R18] Exclusion criteria included (1) known hepatic, biliary or bone disease (114 cases); (2) excessive alcohol consumption (112 cases); (3) chronic kidney failure with dialysis on admission (89 cases); (4) no ALP or GRACE score data (72 cases). Finally, the study included 6368 patients with ACS undergoing PCI. The mean duration of hospitalisation was 7.5±4.4 days. [Figure 1](#F1){ref-type="fig"} represents the flowchart of patient selection. All individuals were divided into three groups according to the tertile of ALP level on admission (Tertile 1: ＜66 U/L (n=2123); Tertile 2: 66--85 U/L (n=2123); Tertile 3: ＞85 U/L (n=2122)). This study complies with the Declaration of Helsinki, and Shengjing Hospital of China Medical University Research Ethics Committee approved the research protocol. Written informed consent was formally obtained from all participants.

![Flow diagram of participant selection. ALP, alkaline phosphatase; AMI, Acute Myocardial Infarction; GRACE, Global Registry of Acute Coronary Events; PCI, percutaneous coronary intervention.](bmjopen-2018-025648f01){#F1}

Patient and public involvement {#s2-2}
------------------------------

No patients or public were involved in the present study.

Statistical analysis {#s2-3}
--------------------

Quantitative variables with normal distribution were represented as mean±SD and compared with Kruskal-Wallis H-test. Quantitative variables without normal distribution were represented as median (IQR) and compared with Kruskal-Wallis H-test. Categorical variables are presented as counts and proportions (%) and compared with χ^2^ test. Logistic univariate regressions were performed to evaluate predictors of in-hospital death using 'Enter' (online [supplementary appendices S1-S3](#SP1){ref-type="supplementary-material"}). A multivariate logistic regression model was used to identify independent predictors of in-hospital death using 'Forward: conditional'. Variables with p\<0.05 in univariate analysis were entered a multivariate analysis. ALP was analysed as a continuous variable and categories variable, respectively. Results were reported as ORs with associated 95% CIs. The predictive performance of ALP, GRACE score and GRACE score +ALP was assessed by indices of discrimination (C-statistic), calibration (the Hosmer-Lemeshow test, the Nagelkerke-R^2^) and precision (Brier scores). The C-statistic, which was defined by the area under the receiver operating characteristic (ROC-AUC) curve in relation to in-hospital mortality, was compared using a non-parametric test developed by DeLong *et al*.[@R19] C-statistic values ＞0.5, 0.75, 0.93 were considered as fair, good, very good accuracy. Each model was entered into a logistic regression model to get the individual risk probability of in-hospital death, respectively. The Hosmer-Lemeshow (HL) test and the Nagelkerke-R^2^ from the regression modelling were used as indicators of goodness-of-fit of each risk model and to assess their calibration ability.[@R20] The Brier scores of ALP, GRACE score and GRACE score +ALP were also calculated.[@R21] Lower Brier scores indicated better precision.[@R21] We also used the absolute integrated discrimination improvement (IDI) and category-free net reclassification improvement (NRI) to evaluate improvements in risk prediction quantisation of ALP and GRACE score +ALP0.[@R22] All tests were two-sided, and the statistical significance was defined as p\<0.05. All statistical analyses were performed using the Statistical Analysis System V.9.4.
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Results {#s3}
=======

Participants and baseline characteristics {#s3-1}
-----------------------------------------

[Figure 1](#F1){ref-type="fig"} represents the flowchart of patient selection. The final study cohort consisted of 6 368 patients with ACS undergoing PCI. Clinical characteristics were shown in [table 1](#T1){ref-type="table"}. Tertile 3 group had significantly higher percentages of females, STEMI and moderate or severe calcification, compared with other groups. Tertile 3 group also had a tendency towards increasing systolic blood pressure, heart rate, Troponin-I, albumin, serum glutamic oxaloacetic transaminase (SGOT), serum glutamate-pyruvate transaminase (SGPT), haemoglobin, leucocyte count and platelet count on admission. There was a significant trend of decreasing creatinine in Tertile 3 group. The percentage of thrombolysis in myocardial infarction (TIMI) flow grade 0/1 was significantly lower in Tertile 3 group. Tertile 3 group also had the trend to suffer a higher in-hospital mortality (1.4% vs 0.5% and 0.7%, p=0.007) ([table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics of the population by tertile of ALP, median (IQR), or N (%), or means±SD

  ------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                     Overall (n=6368)     Tertile 1\           Tertile 2\           Tertile 3\           P value
                                                                    ALP\<66 U/L\         ALP 66--85 U/L\      ALP\>85 U/L\         
                                                                    (n=2123)             (n=2123)             (n=2122)             
  -------------------------------------------- -------------------- -------------------- -------------------- -------------------- ---------
  Demographics                                                                                                                     

   Age, years                                  62.2±11.3            62.6±11.3            62.0±11.4            62.0±11.3            0.229

   Male                                        4379 (68.8)          1581 (74.5)          1461 (68.8)          1337 (63.0)          \<0.001

  Medical history                                                                                                                  

   History of diabetes mellitus                2036 (32.0)          668 (31.5)           718 (33.8)           650 (30.6)           0.069

   History of hypertension                     3816 (59.9)          1263 (59.5)          1259 (59.3)          1294 (61.0)          0.474

   History of MI                               614 (9.6)            208 (9.8)            218 (10.3)           188 (8.9)            0.286

   Dyslipidaemia                               4256 (66.8)          1407 (66.3)          1417 (66.7)          1432 (67.5)          0.701

   Prior PCI                                   702 (11.0)           246 (11.6)           247 (11.6)           209 (9.8)            0.106

   Current smoking                             2839 (44.6)          928 (43.7)           957 (45.1)           954 (45.0)           0.612

  Clinical presentation                                                                                                            

   SBP on admission, mm Hg                     135.3±21.9           134.1±21.7           135.8±22.3           135.9±21.8           0.019

   Heart rate on admission, bpm                74.9±14.0            73.7±13.6            75.2±13.8            75.6±14.4            \<0.001

   GRACE score                                 129.1±36.6           128.7±37.4           129.0±35.9           129.7±36.5           0.727

   Diagnosis on admission                                                                                     0.001                

   STEMI                                       2207 (34.7)          710 (33.4)           723 (34.1)           774 (36.5)           

   NSTEMI-ACS                                  4161 (65.3)          1413 (66.6)          1400 (65.9)          1348 (63.5)          

  Laboratory results on admission                                                                                                  

   Troponin-I, ng/mL                           0.40 (0.01, 11.08)   0.22 (0.01, 10.38)   0.44 (0.01, 10.29)   0.67 (0.01, 12.35)   0.001

   Creatinine, umol/L                          72 (61, 85)          73 (63, 87)          72 (61, 84)          71 (59, 85)          \<0.001

   Albumin, g/L                                39.5±3.9             39.1±3.7             39.6±3.6             39.8±4.3             \<0.001

   SGOT, U/L                                   30 (19, 90)          28 (18, 81)          28 (18, 85)          35 (21, 104)         \<0.001

   SGPT, U/L                                   28 (17, 48)          26 (17, 45)          26 (17, 44)          33 (20, 55)          \<0.001

   ALP, U/L                                    77.3±24.3            53.6±9.7             74.6±5.5             103.6±19.7           \<0.001

   Haemoglobin, g/L                            136.2±17.4           135.4±16.6           136.3±17.4           136.7±18.0           0.017

   Leucocyte count (×10^9^/L)                  8.25±3.24            7.89±3.11            8.20±2.85            8.68±3.63            \<0.001

   Platelet count (×10^9^/L)                   205.4±59.6           197.6±58.4           204.3±56.2           214.3±62.9           \<0.001

   BNP, ng/L                                   122 (42, 338)        121 (42, 338)        116 (41, 313)        128 (43, 356)        0.168

  Percutaneous coronary intervention details                                                                                       

   Moderate or severe calcification            400 (6.3)            110 (5.2)            141 (6.6)            149 (7.0)            0.034

   Left main disease                           553 (8.7)            186 (8.8)            195 (9.2)            172 (8.1)            0.453

   Three-vessel disease                        1636 (25.7)          555 (26.1)           563 (26.5)           518 (24.4)           0.245

   Use of intra-aortic balloon pump            192 (3.0)            63 (3.0)             66 (3.1)             63 (3.0)             0.953

   TIMI flow grade 0/1 on arrival              4930 (77.4)          1684 (79.3)          1640 (77.2)          1606 (75.7)          0.018

   TIMI flow grade three post PCI              6342 (99.6)          2112 (99.5)          2115 (99.6)          2115 (99.7)          0.606

   Duration of hospitalisation, days           7.5±4.4              7.4±4.1              7.6±4.6              7.5±4.5              0.871

   In-hospital mortality                       55 (0.9)             15 (0.7)             29 (1.4)             0.007                
  ------------------------------------------------------------------------------------------------------------------------------------------

ALP, alkaline phosphatase; BNP, brain natriuretic peptide;MI, myocardial infarction; NSTEMI-ACS, non-ST-segment elevation myocardial infarction of acute coronary syndrome; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamate-pyruvate transaminase; STEMI, ST-segment elevation myocardial infarction;TIMI, thrombolysis in myocardial infarction; bpm, beats per minute.

Prognostic performance of ALP in prognosis prediction {#s3-2}
-----------------------------------------------------

The univariate analysis in online [supplementary appendices S1](#SP1){ref-type="supplementary-material"} found that many variables had significant effects on in-hospital mortality: age, systolic blood pressure on admission, heart rate on admission, diagnosis on admission, Troponin-I, creatinine, albumin, SGOT, SGPT, haemoglobin, leucocyte count, brain natriuretic peptide, moderate or severe calcification, left main disease, three-vessel disease, use of intra-aortic balloon pump and TIMI flow grade three post PCI (online [supplementary appendices S1](#SP1){ref-type="supplementary-material"}).

The univariate analysis revealed that ALP was associated with in-hospital mortality (OR: 1.018, 95% CI 1.010 to 1.026, p\<0.001, for per 1 U/L increase) ([table 2](#T2){ref-type="table"}). After adjusting for covariates, the association was still present: an increased in-hospital mortality risk of 1.1% for per 1 U/L increase in ALP concentration (OR: 1.011, 95% CI 1.002 to 1.020, p=0.014) ([table 2](#T2){ref-type="table"}).

###### 

Effects of multiple variables on clinical outcomes in univariate and multivariate analysis

                                 Univariate analysis   Multivariate analysis                                          
  ------------------------------ --------------------- ----------------------- --------- ----------- ---------------- ---------
  GRACE score                    1.034                 1.028 to 1.040          \<0.001                                
  ALP as a continuous variable                                                                                        
  ALP per 1 U/L increase         1.018                 1.010 to 1.026          \<0.001   1.011       1.002 to 1.020   0.014\*
  ALP as a categories variable                                                                                        
   Tertile 1                     Reference                                     0.010     Reference                    0.034
   Tertile 2                     1.366                 0.626 to 2.981          0.433     2.051       0.826 to 5.089   0.122
   Tertile 3                     2.660                 1.325 to 5.339          0.006     3.066       1.309 to 7.179   0.010\*

\*Adjusted for age, SBP on admission, heart rate on admission, diagnosis on admission, Troponin-I, creatinine, albumin, SGOT, SGPT, haemoglobin, leucocyte count, BNP, moderate or severe calcification, left main disease, three-vessel disease, use of intra-aortic balloon pump and TIMI flow grade three post-PCI.

ALP, alkaline phosphatase; PCI, percutaneous coronary intervention; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamate-pyruvate transaminase.

When categorised into three groups, ALP still significantly predicted in-hospital mortality ([table 2](#T2){ref-type="table"}). In the univariate analysis, compared with Tertile 1 and 2 group, Tertile 3 group had a substantially higher risk of in-hospital death (OR: 2.660, 95% CI 1.325 to 5.339, p\<0.001) ([table 2](#T2){ref-type="table"}). In the multivariable analysis, Tertile 3 group still conferred a significantly higher in-hospital mortality (OR: 3.066, 95% CI 1.309 to 7.179, p=0.010) ([table 2](#T2){ref-type="table"}).

The C-statistic of ALP, GRACE score and GRACE score +ALP in predicting in-hospital mortality were 0.630 (95% CI 0.618 to 0.642), 0.842 (95% CI 0.833 to 0.851) and 0.847 (95% CI 0.838 to 0.856) ([table 3](#T3){ref-type="table"} and [figure 2](#F2){ref-type="fig"}), respectively. The cut-off value for ALP was 72 U/L with a sensitivity of 0.764 and a speciﬁcity of 0.468.

![Receiver operating characteristic curves of ALP, grace and GRACE +ALP for in-hospital death prediction. ALP, alkaline phosphatase; GRACE, GlobalRegistry of Acute Coronary Events.](bmjopen-2018-025648f02){#F2}

###### 

GRACE, GRACE+ALP and ALP performance for the prognosis prediction

              Discrimination   Calibration   Precision                                      
  ----------- ---------------- ------------- ----------- ---------------- --------- ------- --------
  GRACE       0.842            0.0276        \<0.001     0.833 to 0.851   0.806     0.186   0.0082
  ALP         0.630            0.0412        0.001       0.618 to 0.642   0.496     0.027   0.0085
  GRACE+ALP   0.847            0.0290        \<0.001     0.838 to 0.856   \<0.001   0.102   0.0081

ALP, alkaline phosphatase; GRACE, Global Registry of Acute Coronary Events; HL, Hosmer-Lemeshow.

The study cohort was also divided into two subgroup: STEMI group (STEMI group) and non-STEMI of ACS group (NSTEMI-ACS group). The subgroup analysis was then taken. In STEMI group, ALP was associated with in-hospital mortality in the univariate or multivariable analysis, when ALP was analysed both as a continuous variable and according to three categories (online [supplementary appendices S4](#SP1){ref-type="supplementary-material"}). The same conclusion was also got in NSTEMI-ACS group (online [supplementary appendices S5](#SP1){ref-type="supplementary-material"}).

Improvement of the prognostic performance of grace score +ALP {#s3-3}
-------------------------------------------------------------

[Table 3](#T3){ref-type="table"} presented that the HL p value and the Nagelkerke-R^2^ of GRACE score was the highest; the Brier score of GRACE +ALP was the lowest. However, the new model in which the GRACE score was combined with ALP could not improve the prognostic performance. The prognostic performance of GRACE +ALP was similar to that of GRACE score (C-statistic: z=0.485, p=0.628; IDI: 0.014, p=0.056; NRI: 0.020, p=0.630) ([table 4](#T4){ref-type="table"}). In the subgroup analysis, the prognostic performance of GRACE +ALP was also similar to that of GRACE score in STEMI group (online [supplementary appendices S6](#SP1){ref-type="supplementary-material"}) or NSTEMI-ACS group (online [supplementary appendices S8](#SP1){ref-type="supplementary-material"}).

###### 

Comparisons of the predictive performance of GRACE, GRACE+ALP and ALP for the prognosis prediction

                       z for C-statistic   P for C-statistic   NRI     P for NRI   IDI     P for IDI
  -------------------- ------------------- ------------------- ------- ----------- ------- -----------
  GRACE vs ALP         4.599               \<0.001             0.310   \<0.001     0.046   \<0.001
  GRACE+ALP vs GRACE   0.485               0.628               0.020   0.630       0.014   0.056
  GRACE +ALP vs ALP    5.411               \<0.001             0.272   \<0.001     0.060   \<0.001

ALP, alkaline phosphatase; GRACE, Global Registry of Acute Coronary Events; IDI, integrated discrimination improvement; NRI, net reclassification improvement.

Discussion {#s4}
==========

The present study tested the association between ALP and in-hospital mortality in patients with ACS undergoing PCI. The main findings were as follows: (1) ALP was an independent predictor of in-hospital mortality; (2) the prognostic performance of GRACE score +ALP was similar to GRACE score, and ALP could not improve the prognostic performance of the original GRACE score model.

At first, an independent association was confirmed between ALP and the risk of adverse outcomes in patients with normal kidney function or kidney failure.[@R23]Then, meta-analyses found the association between ALP and the incident of cardiovascular disease.[@R25] Tonelli *et al* first studied the prognostic value of ALP for the prognosis in survivors of myocardial infarction.[@R11] They found that ALP was an independent predictor of adverse outcomes among 4115 participants with a previous myocardial infarction.[@R11] This observation then was verified and extended by other researches that elevated ALP was an independent predictor of adverse outcomes in patients with CAD,[@R12] ACS[@R14] and STEMI.[@R16] However, no study focuses on the prognostic value of ALP for in-hospital mortality in patients with ACS undergoing PCI. This study demonstrated that, in patients with ACS undergoing PCI, ALP was associated with in-hospital mortality. With ALP as a continuous variable, we found that the risk of in-hospital mortality increased 1.1% per U/L increase in ALP concentration (OR: 1.011, 95% CI 1.002 to 1.020, p=0.014). As shown in [table 2](#T2){ref-type="table"}, as a categorical variable, ALP remained associated with in-hospital mortality (OR: 3.066, 95% CI 1.309 to 7.179, p=0.010 for Tertile 3 group vs Tertile 1 and Tertile 2 group).

Although the detailed pathophysiological association between ALP and adverse outcomes in CAD patient needs further evaluation, there are several possible explanations. First, ALP widely expresses in different tissues, and its highest concentrations were in liver, bone and kidney.[@R8] It can hydrolyze inorganic pyrophosphate, which inhibits calcium, phosphate and hydroxyapatite crystal aggregation.[@R8] So, an increased ALP concentration is linked to vascular calcification. The previous study has confirmed the association between serum ALP and coronary artery calcification in CAD patients.[@R9] Our study also found that there was a significantly higher percentage of moderate or severe calcification in the highest ALP group (7.0% vs 5.2% and 6.6%, p=0.034 for Tertile 3 group vs Tertile 1 and Tertile 2 group) ([table 1](#T1){ref-type="table"}). Coronary calcification contributes to atherosclerosis, and is also a predictor of adverse cardiovascular events.[@R5]Although ACS is usually associated with non-calcified fibroatheroma,[@R27] spot calcification still predicts atherosclerotic plaque rupture.[@R28] Furthermore, severe coronary calcification is an independent predictor of worse prognosis in patients undergoing PCI.[@R29] Also, coronary calcification may hamper the process of re-endothelialisation, and be a marker of extensive atherosclerotic disease.[@R29] More important, a higher serum ALP concentration is also an independent predictor of mortality, myocardial infarction, and stent thrombosis in CAD patients after PCI.[@R14] Second, an elevated serum ALP concentration is closely associated with many cardiovascular risk factors, such as C reactive protein,[@R31] metabolic syndrome,[@R31] vitamin D deficiency[@R33] and fibroblast growth factor-23.[@R34] It indicates that ALP may also affect the prognosis of CAD patients by interacting with cardiovascular risk factors.

Considering these results presented, this finding has some clinical value. First, monitoring ALP in patients with ACS may be worth, since it may help us identify the ACS patients at high risk of in-hospital death. Moreover, animal studies showed that, after inhibiting ALP, organic pyrophosphate would accumulate, and vascular smooth muscle cell calcification would be suppressed.[@R35] This indicates that ALP may be a treatment target of coronary calcification.

This study had several limitations. First, this study was prospective and observational, so potential confounders and selection bias could not be completely adjusted. Second, data on serum parathyroid hormone level, serum vitamin D level and dietary vitamin D intake was not obtained, which might affect ALP levels. However, the previous study showed that the association between ALP and mortality was independent of parathyroid hormone or vitamin D.[@R23] Third, ALP is a membrane-bound glycoprotein (metallo-enzyme) with more than 17 circulating isoforms detectable by isoelectric focusing technique.[@R36] We just measured tissue-non-specific ALP, but not each ALP isoforms (liver, kidney and bone), which could change the total ALP activity. However, inorganic pyrophosphate hydrolysis is a non-specific activity and can be driven by each ALP isoform.[@R8] In addition, in this study, coronary calcification was assessed by angiography, which might underestimate the frequency and degree of coronary calcium, compared with by intravascular ultrasound.[@R37]

Conclusion {#s5}
==========

In patients with ACS undergoing PCI, ALP was an independent predictor of in-hospital mortality. The prognostic performance of GRACE score +ALP was similar to GRACE score, and ALP could not significantly improve the prognostic performance of GRACE score.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

Thank Professor Liqiang Zheng for his statistical assistance!

**Contributors:** Zhaoqing Sun conceived and designed the experiments. Tongtong Yu, Yundi Jiao, Jia Song, Dongxu He, Jiake Wu, Zongyu Wen, Na Sun and Weili Duan performed the experiments. Tongtong Yu analyzed the data and wrote the paper. Zhijun Sun revised the paper. All authors had reviewed and agreed on the contents of this paper.

**Funding:** This research project was supported by grants from the Social Development Research Program of Liaoning Province (2011225020).

**Competing interests:** None declared.

**Patient consent for publication:** Parental/guardian consent obtained

**Ethics approval:** This study complies with the Declaration of Helsinki, Shengjing Hospital of China Medical University Research Ethics Committee approved the research protocol.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data availability statement:** All data relevant to the study are included in the article or uploaded as supplementary information.
